TABLE 5.
Study | Design | Units | Inclusion/exclusion | Incomplete empty definition | IE rate | UTI definition | UTI rate |
---|---|---|---|---|---|---|---|
Brubaker (2008) | RCT | 200 units BTA | PVR < 150 ml or SIC | PVR ≥ 200 ml | 43% | 44% | |
Dmochowski (2010) 5 | RCT | Dose ranging: 50–300 units | PVR < 200 ml 8+ UUI per week and ave 8+ voids per day |
PVR > ≥ 200 | 18% 11% SIC |
36% | |
Visco (2012) 7 | RCT | 100 units | PVR < 150 ml 5+ UUI in 5 days |
PVR ≥ 150 with symptoms; or PVR ≥ 300 |
Do not give overall # | Not Reported | 33% |
Nitti (2013) 9 | RCT | 100 units | PVR < 100 ml 3+ UUI in 3 days and ave 8 voids per day |
PVR ≥ 200 with symptoms; or PVR ≥ 350 Retention = PVR ≥ 200 requiring SIC |
I.E. = 5.4%; SIC = 6.1% |
Positive urine culture | 15.5% |
Amundsen (2016) 12 | RCT | 200 units | PVR < 150 ml 6+ UUI in 3 days |
PVR ≥ 200 with symptoms; or PVR ≥ 300 |
20% at any visit | Not Reported | 35% |
Rahnama’i (2017)15 | Retrospective series | Up to 300 Units | Included NGB | De novo CIC rate 24% | |||
Moita (2017)14 | Prospective cohort | 100 Units | Women with idiopathic OAB | Retention requiring ISC 6% at 2 weeks, 0 at 12 weeks.; PVR > 200 6% @ 2 weeks, 0.4% at 12 weeks | Not Reported | Not Reported | |
Patel (2018)8 | Retrospective series | 100 units | Any women undergoing BTX-A injection with ROAB, no PVR limits | <200 200–349 ≥350 |
1% @ 2 weeks | +UCx with symptoms | 36% |
Faure Walker (2019)13 | Retrospective series | Up to 300 units | Men and women | 48.9% de novo CIC in men receiving 100 U; 35.3% in women receiving up to 300 U |
Abbreviations: CIC, clean intermittent catheterization; PVR, postvoid residual; RCT, randomized controlled trial; UTI, urinary tract infection; UUI, urgency urinary incontinence epsidodes.